Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saruparib plus ADT with RT in high‑risk BRCA‑mutated localized/locally advanced prostate cancer
jRCT2031250260Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in prostate cancer (PCa) comparing Saruparib arm with Placebo arm (2 arms). Primary endpoint: Metastasis-free survival. Started Sep 2025; status: recruiting.
02
Drugs
saruparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031250260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250260.